Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Jan 11, 2019 2:34pm
113 Views
Post# 29220234

RE:RE:to lie

RE:RE:to lie
Wino115 wrote: If laziness and ignorance were crimes, sell side analysts would be crowding the prisons around the world.  Don't forget, the vast majority (if not ALL), highly skilled and motivated analysts left the industry years ago to get on the buy side, retire to their yachts in FL, or become consultants/boutique research-for-pay guys. The model that pays them is broken and margins have plummeted with revenues. So for one, most of these guys aren't that good - you saw that with the RBC guy too.  And their compensation is falling and covering small cap biotechs really isn't going to be top of their list.  Hence, the silly and obviously incorrect assumptions and crazy manic/depressive movement of his numbers.

Just ignore the whole thing and wait for facts to come out to make any judgements about the state of the company and their products.  


You're amazingly, consistently rational and lucid for a wino, congratulations :)

Bullboard Posts